Cellular mechanism of action
The effects of these drugs are based on the stimulation of receptors functionally coupled to Gs-proteins. This interaction leads to the stimulation of the enzyme adenylyl cyclase and the subsequent accumulation of intracellular cAMP. This second messenger activates cAMP-dependent protein kinase A (PKA), which triggers two independent cascades leading to the relaxation of smooth muscle cells:
- Myosin pathway: PKA inhibits myosin light-chain kinase. Without the phosphorylation of these chains, the interaction between actin and myosin filaments is completely blocked.
- Calcium pathway: The enzyme inhibits phospholamban, which normally inhibits the calcium ATPase of the sarcoplasmic reticulum (SR). As a result, calcium ions are actively pumped out of the cytoplasm back into the storage depot, and their concentration drops.
The outcome of both cascades is a rapid decrease in tone and loss of the cell's contractile capacity.
Classification and pharmacokinetics
Their chemical structure (all are phenethylamine derivatives) directly determines the onset and duration of the effect. These molecules are modified compared to endogenous catecholamines, making them resistant to degradation by the enzyme COMT.
- Short-acting agents (SABA): Representatives include salbutamol, fenoterol, terbutaline, hexoprenaline. The effect upon inhalation appears within 1–5 minutes and lasts for 4–6 hours. Salbutamol contains a tert-butyl group at the nitrogen atom, which ensures selectivity.
- Long-acting agents (LABA): Representatives include salmeterol, formoterol, clenbuterol. Their key difference is the presence of a long lipophilic "tail". High lipophilicity allows the molecule (especially salmeterol) to penetrate deeply into the membrane and form a depot near the receptor, ensuring an action lasting over 12 hours. Due to strong binding to the lipid bilayer, the effect of salmeterol develops slowly (with a latency period of up to 30 minutes). In contrast, formoterol is released faster, combining an immediate onset of action with a prolonged effect.
Clinical application
Drugs are widely used in two independent medical fields:
- Pulmonology: Used in bronchial asthma and COPD. They dilate predominantly small and medium-sized bronchi (where receptor density is highest). Additionally, they reduce the release of mediators from mast cells and stimulate mucociliary clearance. Short-acting agents act as "emergency" relief for acute attacks. Long-acting agents are prescribed for maintenance therapy. Combination therapy is frequently used: a $\beta_2$-agonist is combined with an antimuscarinic agent (e.g., fenoterol + ipratropium bromide in the drug Berodual) for synergy.
- Obstetric practice: Tocolytic action—the ability to reduce myometrial tone—is utilized. Hexoprenaline and fenoterol are used for threatened miscarriage or preterm labor. There is a risk of drugs crossing the placental barrier and causing fetal tachycardia (especially with the use of salbutamol).
Systemic and adverse effects
The selectivity of modern drugs is not absolute; therefore, characteristic adverse reactions develop at high doses or with systemic administration:
- Cardiovascular system: Decreased diastolic blood pressure due to peripheral vasodilation. Tachycardia develops through three mechanisms: reflex response to hypotension, direct stimulation of receptors in the atria, and partial activation of cardiac $\beta_1$-receptors.
- Neuromuscular system: Clinically significant tremor occurring due to the stimulation of skeletal muscle $\beta_2$-рецепторов.
- Metabolism: Activation of phosphorylase in the liver causes glycogenolysis and hyperglycemia. Potassium uptake by cells is also enhanced, leading to hypokalemia.
Briefly: answers to topical questions
Which drug classes are combined with beta-2 adrenergic agonists in the treatment of bronchial asthma and COPD?
In the treatment of bronchial asthma, beta-2 adrenergic agonists can be combined with inhaled glucocorticosteroids, such as formoterol with a glucocorticoid (Symbicort). In COPD, a combination of a beta-2 adrenergic agonist with an antimuscarinic agent is used; triple therapy is possible: long-acting beta-agonist + long-acting anticholinergic + inhaled glucocorticosteroid. An example of a beta-2 adrenergic agonist combined with an antimuscarinic agent is fenoterol and ipratropium bromide (Berodual).
What are the contraindications for prescribing beta-2 adrenergic agonists?
A contraindication to prescribing beta-2 adrenergic agonists as tocolytics is the early postpartum period during the management of hypotonic hemorrhage. In this situation, drugs (e.g., salbutamol) relax the uterus, which can increase bleeding. Furthermore, combination cough medications containing salbutamol, bromhexine, and guaifenesin are contraindicated during pregnancy and breastfeeding.
What changes in chemical structure make beta-2 adrenergic agonists resistant to the COMT enzyme?
The resistance of beta-2 adrenergic agonists to the action of the COMT enzyme is provided by differences in their chemical structure compared to catecholamines: the presence of hydroxyl groups at positions 3 and 5 instead of 3 and 4 in fenoterol and terbutaline, or modification of the aromatic ring at position 3 in salbutamol, salmeterol, and formoterol. These alterations ensure a longer duration of effect compared to endogenous catecholamines.
Target organs are easy to remember using the "three B's" rule: Bronchi (dilation), Bun/Pregnancy (uterine relaxation), Beating heart (tachycardia).
Class and exam questions
Why is salmeterol not used to relieve an acute asthma attack?
Due to its extremely high lipophilicity, the molecule becomes firmly "trapped" in the lipid layer of the cell membrane. Its rate of diffusion to the receptor is low, so the bronchodilator effect occurs only after 30 minutes, which is unacceptable in emergency care.
How do beta-2 adrenergic agonists affect glucose and potassium levels?
They cause transient hyperglycemia due to the stimulation of glycogenolysis in the liver and skeletal muscles. Concurrently, hypokalemia develops because the receptors stimulate the active transport of potassium from blood plasma into cells.
What is the advantage of combining fenoterol with ipratropium bromide in COPD?
This combination of a $\beta_2$-adrenergic agonist and an antimuscarinic agent leads to a mutual enhancement of the bronchodilating effect (synergy). This makes it possible to reduce the dose of each component and decrease the severity of adverse effects.
What else to study on this topic
- Chemical differences between resorcinol derivatives and catecholamines
- The role of the membrane exosite in prolonging the action of salmeterol
- Molecular mechanism of mast cell membrane stabilization upon beta-2 receptor stimulation
- Indications and limitations for the use of non-selective orciprenaline
- Pharmacokinetic features of oral and subcutaneous forms of salbutamol
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Beta-2 adrenergic agonists" and 5,304 other subject pages
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the section "Drugs Acting on Adrenergic Synapses"
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.